SINO BIOPHARM Reports 12.3% Increase in Interim Net Profit to RMB3.389 Billion; Interim Dividend Per Share Reaches HKD5 Cents

The article provides a list of stocks with their current prices, short selling data, and analyst ratings. All the listed stocks have a "Buy" rating, indicating that analysts believe these stocks are a good investment opportunity. The reasons for the "Buy" ratings are not explicitly stated in the provided text, but the presence of short selling data and the ratios may suggest that analysts see potential for price recovery or growth despite current short selling pressures. Additionally, the mention of "Order Momentum Remains Strong" for WUXI XDC implies that there is positive sentiment regarding its future performance, even though it has a neutral rating from G Sachs.

The analyst rating from Guotai Junan for SINO BIOPHARM is a Buy, with a target price of HKD10. The reasons for this rating include: 1. Enhanced Innovation Capabilities: SINO BIOPHARM has improved its ability to innovate, which positions it well in the competitive healthcare sector. 2. Global Layout: The company has established a global presence, which can enhance its market opportunities and growth potential. 3. Improved Capital Market Sentiment: There has been a rebound in investment sentiment within China's healthcare sector, benefiting companies like SINO BIOPHARM. 4. Strong Market Position: As one of China's largest and most well-developed drug makers, SINO BIOPHARM has significant scale, financing capabilities, and commercial infrastructure. 5. Acquisition Potential: The company is well-positioned to acquire promising local biotech firms, which can accelerate the development and commercialization of new assets. These factors collectively contribute to a positive outlook for the company's earnings and growth prospects in the coming years.